Skip to content

Effect of Kiwifruit on Gastrointestinal Fluid Distribution and Transit in Healthy Volunteers

Effect of Kiwifruit on Gastrointestinal Fluid Distribution and Transit in Healthy Volunteers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03303417
Acronym
KIWI
Enrollment
16
Registered
2017-10-06
Start date
2017-06-27
Completion date
2018-06-01
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation, Diet Modification

Keywords

Kiwifruit

Brief summary

Constipation is a widespread and common problem in which a person finds it difficult and/or painful to open their bowels. The current treatment is the use of medications called laxatives. Kiwifruit is a widely available food that has been shown to possess some laxative properties. The cause of this is unknown. Non-invasive medical imaging techniques such as Magnetic Resonance Imaging now allow taking pictures of the gut and its contents. The Nottingham GI MRI research group specialises in these techniques and in this study use such images to assess the changes induced in the gut contents by kiwifruit to improve understanding of how it helps patients with constipation. The volunteers will be asked to undergo 2 studies in which they take either kiwifruit or placebo (sugary drink) two times a day for 2 days and then spend a study day where will they will be fed some more kiwifruit/placebo and some normal food and image their gut at intervals. Participants will be asked to complete a stool diary to determine if they experience a laxative effect.

Detailed description

1. Background. Chronic constipation affects approximately 17% of the population worldwide and remains an important unmet need since patients are currently often dissatisfied with treatment Current treatments which stimulate propulsive colonic motility or osmotic laxatives are successful in increasing stool frequency but are often associated with bloating, cramps and abdominal discomfort. Furthermore, such powerful treatments taken intermittently often create abnormal colonic contents and may result in alternation between diarrhoea and no stools. Many patients would benefit from a less powerful treatment which could be taken daily. Kiwifruit offer such an alternative and have been shown to increase stool volume and frequency. The mode of action however is unclear. Kiwi is 3% fibre (approximately 1/3 insoluble) and contains around 3% nonstarch polysaccharide including pectins, hemicellulose and cellulose, with high water holding capacity 1.5 times that of ispaghula, a commonly used laxative. Using recently developed and validated novel non-invasive MRI techniques, the University can assess transit and fluid distribution in the small intestine \[4\]. The University has also developed methods to assess colonic fluid, volumes and motility. 2. Aims. To assess the effect of kiwifruit on gastrointestinal fluid distribution. 3. Experimental protocol and methods. A randomised, placebo controlled, 2-way cross-over study in N=15 healthy volunteers assessing the response (versus baseline values) of 2 kiwifruit b.d vs placebo (28 gm maltodextrin drink providing 120kcal equal to that of 2 kiwifruit) daily. After a screening visit to confirm eligibility, study subjects will be randomised as to the test product schedule. Subjects will complete a daily stool diary documenting stool frequency and consistency using the Bristol Stool Form Scale. They will consume the test product allocated starting on Day 4. At 9 am of the morning of Day 5 they will ingest 5 MRI transit markers as described below and note the time of ingestion. The markers will be imaged at 24 hours (baseline scan of Day 6). On the main study day, the subjects will arrive fasted overnight and undergo fasting scans before consuming that day's allocated test product with 250ml of water. After 30 minutes considered to be Time =0 they will consume a standard rice pudding meal as used in previous studies. They will then undergo serial scanning hourly for 7 hours taking the second dose of test product plus 250ml water at Time 180 minutes. The third dose is taken at 320 minutes followed at 380 minutes by a second, larger test meal consisting of 400 g microwaveable macaroni cheese ready meal (Sainsbury), 100 g cheesecake slice (Sainsbury), and 250 mL bottled still water. The second test meal provides approx. 1000 kcal. The final scan will at time 420 minutes to assess the effect of ileal emptying on gastrointestinal fluid distribution. They will then be allowed home. There will be 2 weeks between studies to ensure return to baseline. At the end of the study a further 3 participants will be scanned in exactly the same protocol however at a lower dose of kiwifruit (2 fruit once daily) to determine if the effect is still visible. 4. Measurable end points/statistical power of the study. Primary endpoint: Effect of Kiwifruit on Ascending colon T1 area under curve from time 0-420. Secondary endpoints: Effect of Kiwifruit on the following measures both fasting and postprandial AUC 0-420 minutes: 1) small bowel water content 2) ascending (AC), transverse (TC) and descending (DC) colonic volumes. 3) Transit of markers through gut as assessed by the weighted position score at 24 h (WAPS24) 4) Colonic motility 5) Gastric emptying of test meal 6) T1 of AC and DC. Pilot data with a standard laxative dose of ispaghula 7g t.d.s. showed a change of T1 AUC 0-360 of mean (SD) 88 (55) sec.min . Using this data n=15 healthy volunteers will give us \>90% power to detect such a difference.

Interventions

DIAGNOSTIC_TESTMRI Scan

Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content

Kiwifruit

OTHERcalorie-matched sugar drink

calorie-matched sugar drink

Sponsors

University of Nottingham
Lead SponsorOTHER
Zespri International Limited
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Masking description

MRI analysis will be performed blind to the intervention

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers scoring within the normal range for bowel symptoms as assessed using the GSRS, aged 18-65 years.

Exclusion criteria

1. Inability to discontinue medication likely to alter GI transit. 2. Previous gastrointestinal surgery (excluding cholecystectomy and appendectomy). 3. Known inflammatory bowel disease, coeliac disease. 4. Known intolerance of kiwifruit. 5. Inability to discontinue drugs likely to alter gut transit. 6. Subjects considered by the investigator unlikely to comply with study protocol.

Design outcomes

Primary

MeasureTime frameDescription
Relaxation Time in Ascending Colon0 - 8 hoursArea under curve of Ascending colon T1 measured on MRI , in milliseconds. Measurements at 0, 1, 2, 3, 4, 5, 6, 7, and 8 hours post-intervention

Secondary

MeasureTime frameDescription
Small Bowel Water Content Measured by MRI, in mL0 - 8 hoursArea under the curve of change of small bowel water, 0-8 hours, measured by MRI, in mL Measurements at 0, 1, 2, 3, 4, 5, 6, 7, and 8 hours post-intervention
Colonic Volume0 - 8 hoursAscending (AC), transverse (TC) and descending (DC) colonic volumes, measured by MRI, in mL Data given: AUC for total colon Measurements at 0, 1, 2, 3, 4, 5, 6, 7, and 8 hours post-intervention
Colonic Transit Time24hrTransit of markers through gut as assessed by the weighted average position score (total score 0-7, calculated from a score of 0-7 of each of the 5 marker pills) at 24 h on MRI A lower score indicates faster transit.
Bowel Habit7 daysAssessment, via Diary, of bowel frequency Data given: stool frequency

Countries

United Kingdom

Participant flow

Recruitment details

16 healthy volunteers were recruited from the population of Nottingham and surroundings. 2 dropped out after a single visit due to unexpected work commitments so 14 volunteers completed the study

Participants by arm

ArmCount
All Study Participants
All participants randomised to either Kiwifruit then Control or Control then Kiwifruit Interventions
14
Total14

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject11

Baseline characteristics

CharacteristicAll Study Participants
Age, Continuous26 years
BMI23 kg/m^2
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United Kingdom
14 Participants
Sex: Female, Male
Female
6 Participants
Sex: Female, Male
Male
8 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 140 / 14
other
Total, other adverse events
0 / 140 / 14
serious
Total, serious adverse events
0 / 140 / 14

Outcome results

Primary

Relaxation Time in Ascending Colon

Area under curve of Ascending colon T1 measured on MRI , in milliseconds. Measurements at 0, 1, 2, 3, 4, 5, 6, 7, and 8 hours post-intervention

Time frame: 0 - 8 hours

ArmMeasureValue (MEAN)Dispersion
KiwifruitRelaxation Time in Ascending Colon312 seconds*minutesStandard Deviation 92
ControlRelaxation Time in Ascending Colon256 seconds*minutesStandard Deviation 97
Secondary

Bowel Habit

Assessment, via Diary, of bowel frequency Data given: stool frequency

Time frame: 7 days

ArmMeasureValue (MEAN)Dispersion
KiwifruitBowel Habit1.46 stools per dayStandard Deviation 0.66
ControlBowel Habit1.14 stools per dayStandard Deviation 0.46
Secondary

Colonic Transit Time

Transit of markers through gut as assessed by the weighted average position score (total score 0-7, calculated from a score of 0-7 of each of the 5 marker pills) at 24 h on MRI A lower score indicates faster transit.

Time frame: 24hr

ArmMeasureValue (MEDIAN)
KiwifruitColonic Transit Time0.8 Score on a scale
ControlColonic Transit Time1.0 Score on a scale
Secondary

Colonic Volume

Ascending (AC), transverse (TC) and descending (DC) colonic volumes, measured by MRI, in mL Data given: AUC for total colon Measurements at 0, 1, 2, 3, 4, 5, 6, 7, and 8 hours post-intervention

Time frame: 0 - 8 hours

ArmMeasureValue (MEAN)Dispersion
KiwifruitColonic Volume283583 ml*minutesStandard Deviation 59402
ControlColonic Volume243182 ml*minutesStandard Deviation 46682
Secondary

Small Bowel Water Content Measured by MRI, in mL

Area under the curve of change of small bowel water, 0-8 hours, measured by MRI, in mL Measurements at 0, 1, 2, 3, 4, 5, 6, 7, and 8 hours post-intervention

Time frame: 0 - 8 hours

Population: 14 participants completed the study

ArmMeasureValue (MEAN)Dispersion
KiwifruitSmall Bowel Water Content Measured by MRI, in mL85530 ml*minutesStandard Deviation 34923
ControlSmall Bowel Water Content Measured by MRI, in mL35023 ml*minutesStandard Deviation 15557

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026